We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Genetic Variations Increase Heart Attack Risk for Statin Patients

By LabMedica International staff writers
Posted on 22 May 2018
Print article
Image: A diagram of the causes of coronary heart disease (Photo courtesy of US National Heart, Lung and Blood Institute).
Image: A diagram of the causes of coronary heart disease (Photo courtesy of US National Heart, Lung and Blood Institute).
Coronary heart disease (CHD) is a leading cause of death globally. Although therapy with HMG-CoA reductase inhibitors (statins) decreases circulating levels of low-density lipoprotein cholesterol (LDL-C) and the incidence of CHD, additional events occur despite statin therapy in some individuals.

Genetic variations have been discovered that increase the risk of heart attack even when patients are receiving a statin drug to lower their blood cholesterol. This may help to explain why some patients experience a heart attack or the need for coronary revascularization to open blocked heart arteries while taking statins. The discovery suggests that drugs targeting the genetic variations could lower the heart risk in these patients.

A large team of scientists led by those at Vanderbilt University Medical Center (Nashville, TN, USA) performed a two-stage genome-wide association study (GWAS) of CHD events during statin therapy. They first identified 3,099 cases that experienced CHD events (defined as acute myocardial infarction or the need for coronary revascularization) during statin therapy and 7,681 controls without CHD events during comparable intensity and duration of statin therapy. They then sought replication of candidate variants in another 160 cases and 1,112 controls performed a phenome-wide association study (PheWAS) for other traits linked to the most significant locus.

The investigators were able to identify seven genetic variations, called single nucleotide polymorphisms or SNPs, in the Lipoprotein(A) (LPA) locus of genes that were associated with these heart events in patients receiving statin treatment. The LPA gene encodes apolipoprotein (a), a fatty protein that binds to low-density lipoprotein (LDL), the form of blood cholesterol that is the target of statin drugs. High levels of bound LDL, called Lp(a) for short, is well known to be an independent risk factor for heart disease.

One of the SNPs was highly associated with an increased risk of heart events. When the team examined the full electronic health records (EHRs) of 11,566 individuals who carried the SNP for more than 1,000 physical conditions, they found significantly higher rates of coronary heart disease and heart attack but not of other diseases. Joshua C. Denny, MD, MS, a Professor of Biomedical Informatics and Medicine and a leading author of the study, said, “People with these genetic variants were at a higher risk for heart disease, even considering those who have ideal cholesterol levels on their statin.”

The authors concluded that a genetic variation at the LPA locus is associated with CHD events during statin therapy independent of the extent of LDL-C lowering. This finding provides support for exploring strategies targeting circulating concentrations of lipoprotein(a) to reduce CHD events in patients receiving statins. The study was published on April 27, 2018, in the journal Circulation.

Related Links:
Vanderbilt University Medical Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.